Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

**HETLIOZ® (tasimelteon)**

Full HETLIOZ® Prescribing Information can be found at: [www.hetlioz.com](http://www.hetlioz.com).

**Fanapt® (iloperidone)**
Fanapt® is an atypical antipsychotic approved for the treatment of schizophrenia in adults. Fanapt® is a serotonin (5-HT2) receptor and dopamine receptor antagonist.

Fanapt® received U.S. Food and Drug Administration approval in May 2009. In addition, Vanda currently has Fanapt® distribution partnerships in Israel and Mexico. In 2012, Fanapt® was approved for marketing in Israel and Argentina.

For U.S. full prescribing information, including box warnings and safety information, please visit [www.fanapt.com](http://www.fanapt.com).